Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Gains from Sales and Divestitures (2019 - 2025)

Historic Gains from Sales and Divestitures for Cytosorbents (CTSO) over the last 7 years, with Q3 2025 value amounting to $264835.0.

  • Cytosorbents' Gains from Sales and Divestitures fell 1088.07% to $264835.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $264835.0, marking a year-over-year decrease of 1088.07%. This contributed to the annual value of $297169.0 for FY2024, which is 37547.04% up from last year.
  • Latest data reveals that Cytosorbents reported Gains from Sales and Divestitures of $264835.0 as of Q3 2025, which was down 1088.07% from $139000.0 recorded in Q2 2025.
  • Cytosorbents' Gains from Sales and Divestitures' 5-year high stood at $297169.0 during Q3 2024, with a 5-year trough of $20000.0 in Q2 2024.
  • In the last 5 years, Cytosorbents' Gains from Sales and Divestitures had a median value of $78589.0 in 2023 and averaged $130283.8.
  • Per our database at Business Quant, Cytosorbents' Gains from Sales and Divestitures plummeted by 7710.21% in 2022 and then surged by 59500.0% in 2025.
  • Over the past 5 years, Cytosorbents' Gains from Sales and Divestitures (Quarter) stood at $196525.0 in 2021, then crashed by 77.1% to $45000.0 in 2022, then surged by 38.89% to $62500.0 in 2023, then surged by 375.47% to $297169.0 in 2024, then dropped by 10.88% to $264835.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $264835.0 for Q3 2025, versus $139000.0 for Q2 2025 and $65000.0 for Q1 2025.